Management of fertility preservation in young breast cancer patients in a large breast cancer centre
- First Online:
- Cite this article as:
- Lawrenz, B., Neunhoeffer, E., Henes, M. et al. Arch Gynecol Obstet (2010) 282: 547. doi:10.1007/s00404-010-1523-0
- 193 Downloads
The increase of breast cancer in young women under 40 years and the increasing age of women at the time of the birth of their first child underlines the importance to implement counselling for fertility-preserving strategies in the management of breast cancer care. We present the fertility-preserving procedures performed after routine counselling for primary breast cancer patients in a large certified breast cancer centre.
Materials and methods
Since November 2006, patients aged below 40 years with histologically confirmed breast cancer are routinely counselled on fertility-preserving possibilities before breast surgery and chemotherapy in the fertility centre of the University Women’s Hospital in Tuebingen. The recommendations are based on the treatment recommendations of the network FertiPROTEKT.
During the last 40 months, 56 primary breast cancer patients were counselled. Forty-one of these patients were hormone receptor positive. Thirty-four patients (63%) underwent fertility-preserving strategies. The majority of the patients (n = 22) decided on ovarian tissue cryopreservation. GnRH protection was performed in 14 patients. In 12 patients an ovarian stimulation protocol was initiated to cryopreserve fertilized or unfertilized oocytes. A combination of different fertility-preserving methods was performed in 12 patients.
The preservation of ovarian function and fertility are of great importance to young breast cancer patients. Counselling on fertility-preserving strategies is therefore critical in these patients and should be routinely performed.
KeywordsBreast cancer chemotherapy Fertility Fertility-preserving methods Cryopreservation
Cyclophosphamide, methotrexate, fluorouracil
Fluorouracil, epirubicin, cyclophosphamide
Fluorouracil, adriamycin, cyclophosphamide